Top in rheumatology: Sotrovimab for COVID-19, Xeljanz for ankylosing spondylitis
Click Here to Manage Email Alerts
The FDA recently authorized sotrovimab to treat mild-to-moderate COVID-19 in individuals aged 12 years and older who are not hospitalized or require oxygen. The announcement was the top story in rheumatology last week.
Another top story shared study data on tofacitinib (Pfizer) as a treatment for adults with ankylosing spondylitis. The Janus kinase inhibitor exhibited significantly higher response rates compared with placebo.
Read these and more top stories in rheumatology below:
FDA issues EUA for sotrovimab, third monoclonal antibody to treat COVID-19
The FDA has issued an emergency use authorization for the monoclonal antibody sotrovimab sotrovimab (VIR-7831, GlaxoSmithKline) to treat mild-to-moderate COVID-19 in patients at risk for progressing to severe disease, according to a press release. Read more.
Tofacitinib displays 'significantly greater' efficacy vs. placebo in ankylosing spondylitis
Tofacitinib 5 mg twice daily demonstrated “significantly greater” efficacy than placebo in adults with ankylosing spondylitis, according to researchers writing in the Annals of the Rheumatic Diseases. Read more.
UCLA questionnaire may shed light on gastrointestinal burdens of systemic sclerosis
A questionnaire developed at the University of California, Los Angeles, can discriminate patients with systemic sclerosis who have an indication for esophago-gastro-duodenoscopy, according to data published in Arthritis Research & Therapy. Read more.
Erosive hand osteoarthritis linked to greater radiographic progression, structural damage
Erosive hand osteoarthritis tends to target older adults and women with preexisting OA, and is associated with severe articular structural damage and radiographic progression, according to data published in Arthritis & Rheumatology. Read more.
Methotrexate plus pegloticase improves gout evaluations, patient outcomes at 1 year
Concomitant use of methotrexate and pegloticase resulted in “meaningful” improvements in joint assessments and patient-reported outcomes at 12 months in uncontrolled gout, according to data presented at the EULAR 2021 Virtual Congress. Read more.